Phase 2CompletedAge-related condition

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (Wet AMD)

Sponsor
Unity Biotechnology, Inc. (Industry)
Enrollment
51 enrolled
Conditions
Neovascular Age-related Macular Degeneration
Interventions
UBX1325 injection 50 μL; EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Ages
adults, older adults
Registry
NCT05275205

Full record on ClinicalTrials.gov

From the registry

This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.

Primary outcomes

  • Treatment Emergent Adverse Events (TEAEs) Will be Evaluated for Ocular and Systemic Safety and Tolerability of a Repeat IVT Injection of UBX1325 Compared to Active Control

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started